Publications by authors named "G E Hart"
Far-field (9.7-35.5 km) noise measurements were made during the fifth flight test of SpaceX's Starship Super Heavy, which included the first-ever booster catch.
View Article and Find Full Text PDFArticle Synopsis
- SPL84 is an antisense oligonucleotide (ASO) drug designed to treat cystic fibrosis by correcting splicing issues in the CFTR gene, which are caused by a specific mutation leading to non-functional proteins.
- In a phase 1 clinical trial with 32 healthy individuals, SPL84 was tested for safety and tolerability compared to a placebo, without significant adverse effects observed.
- The results indicated that SPL84 was well-tolerated, with low systemic exposure suggesting it is safe for further development in treating cystic fibrosis.
Introduction: Non-consensual condom removal (NCCR) refers to the act of removing a condom during sex without the other person's permission. It poses physical and psychological risks to women's health. Views and attitudes regarding this sexual practice are not well understood in the UK.
View Article and Find Full Text PDFFrom Fringe to the Mainstream: How ETD MS Brought O-GlcNAc to the Masses.
Mol Cell Proteomics
November 2024
O-GlcNAcylation was identified in the 1980s by Torres and Hart and modifies thousands of cellular proteins, yet the regulatory role of O-GlcNAc is still poorly understood compared to the abundance of mechanistic information known for other cycling post-translational modifications like phosphorylation. Many challenges are associated with studying O-GlcNAcylation and are tied to the technical hurdles with analysis by mass spectrometry. Over the years, many research groups have developed important methods to study O-GlcNAcylation revealing its role in the cell, and this perspective aims to review the challenges and innovations around O-GlcNAc research and chronicle the work by Donald F.
View Article and Find Full Text PDFThe replacement of chloroquine with artemisinin-based combination therapies (ACTs) for over a decade has had varying impacts on the ability of the malaria parasite to sustain its chloroquine resistance prowess in different malaria-endemic regions. We evaluated the frequency of Plasmodium falciparum chloroquine resistance transporter (PfCRT) mutations in Ibadan, Nigeria 17 years after the replacement of chloroquine with ACTs for malaria treatment. Fragments of PfCRT gene from genomic DNA of microscopically confirmed P.
View Article and Find Full Text PDF